ESSA Pharma Inc.
NASDAQ Capital MarketTotal Valuation
ESSA Pharma Inc. carries a market capitalization of 9.52M, placing it among publicly traded companies globally. Its enterprise value stands at -34.17M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 9.52M |
| Enterprise Value | -34.17M |
Share Statistics
ESSA Pharma Inc. currently has 44.39M shares outstanding.
| Shares Outstanding | 44.39M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 1.42 |
| P/TBV Ratio | 0.69 |
| P/FCF Ratio | -3.61 |
| P/OCF Ratio | -3.61 |
Financial Position
ESSA Pharma Inc. maintains a current ratio of 69.07, meaning it holds 69.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 69.07 |
| Quick Ratio | 68.84 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -38.56 |
| Return on Assets (ROA) | -20.78 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
ESSA Pharma Inc.'s stock has declined approximately -89.1828% over the past 52 weeks. The 50-day moving average sits at 0.83, while the 200-day moving average is 1.49.
| Beta (5Y) | N/A |
| 52-Week Price Change | -89.1828% |
| 50-Day Moving Average | 0.83 |
| 200-Day Moving Average | 1.49 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -29.40M, while operating income came in at -29.49M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -29.49M |
| Pretax Income | -25.27M |
| Net Income | -25.27M |
| EBITDA | -29.40M |
| EBIT | -29.49M |
| Earnings Per Share (EPS) | -0.57 |
Balance Sheet
Total book value stands at 52.95M, with working capital of 108.90M providing operational flexibility.
| Cash & Cash Equivalents | 109.62M |
| Total Debt | N/A |
| Net Debt | -85.95M |
| Equity (Book Value) | 52.95M |
| Book Value Per Share | 1.19 |
| Working Capital | 108.90M |
Cash Flow
ESSA Pharma Inc. produced -20.88M in operating cash flow over the past twelve months.
| Operating Cash Flow | -20.88M |
| Capital Expenditures | N/A |
| Free Cash Flow | -20.88M |
| FCF Per Share | -0.47 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.08 |
| FCF Yield | -27.68 |
Stock Splits
ESSA Pharma Inc.'s most recent stock split took place on April 25, 2018 with a 20:1 split ratio.
| Last Split Date | 4/25/2018 |
| Split Ratio | 20:1 |
Scores
ESSA Pharma Inc. posts an Altman Z-Score of 25.72, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 25.72 |